36 States Bid for Sematech Center

WASHINGTON—Thirty-Six states would like to be home to the central research facility for a proposed $250 million-a-year program aimed at developing cheaper and better semiconductors. Congress, spurred by concern over declining U.S. competitiveness, is preparing to pour up to $100 million a year into the joint government-industry venture. An industry panel assigned the task of picking a site for the semiconductor technology program—known as Sematech—has been “overwhelme

Written byDan Charles
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

WASHINGTON—Thirty-Six states would like to be home to the central research facility for a proposed $250 million-a-year program aimed at developing cheaper and better semiconductors.

Congress, spurred by concern over declining U.S. competitiveness, is preparing to pour up to $100 million a year into the joint government-industry venture. An industry panel assigned the task of picking a site for the semiconductor technology program—known as Sematech—has been “overwhelmed with the volume of proposals,” said Bob Burger, vice president of the Semiconductor Research Corporation in North Carolina. Set up in 1982, SRC is an industry-funded program to do fundamental research in semiconductor technology.

The Sematech facility would provide working space and equipment for an estimated 500 scientists and engineers. About half the professional employees would rotate in and out from the major semiconductor firms participating in the project, said Larry Sumney, president of SRC and managing director of Sematech.

Although a decision ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies